$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
CCI is a widely used peripheral nerve injury model of chronic neuropathic pain. It is relatively simple to perform, and produces robust and stable pain hypersensitivity for at least one month after injury. Following CCI, rats exhibit abnormal posture of the injured hindpaw (toes held together and plantar-flexed and paw everted), as well as repeated shaking, guarding and licking of the injured hindpaw suggesting the presence of spontaneous pain9. In addition to sensory dysfunction, several investigators have shown that CCI evokes behavioural disabilities, such as disrupted social interactions, sleep disturbances, depressive-like and anxiety-like behaviours10-13, however this is in contrast to the failure to find such behavioural disabilities by others14,15. CCI is therefore commonly used to investigate both the pathophysiology, and potential therapeutic agents for treatment of neuropathic pain.
We describe unilateral constriction of the left sciatic nerve, however it should be noted that many experimenters have performed CCI on the right sciatic nerve, with similar pain and behavioural outcomes. Some investigators may find it easier to perform surgery on a specific side due to handedness, whilst others have switched sides within experiments to rule out any bias. It is noteworthy that several variations to the original procedure have been reported including using only 2 ligatures around the nerve16,17 and using suture material other than chromic gut such as plain gut and polyglactin (vicryl)18,19 in rats. In addition, the CCI model has also been modified for use in mice, where the procedure is identical, except for the use of 2-3 ligatures with various suture materials including chromic gut, nylon, and prolene15,20,21.
One limitation of this model is the degree of variation amongst the rats subjected to CCI, due to variability in the tightness of the constrictions produced by tying knots with the sutures. This can be partially overcome by having an experienced researcher performing the surgery in a consistent way. Furthermore, the type of suture material used for ligating the nerve can also contribute to variability, and it is believed that chemicals from the chromic gut mediate some of the behavioural and neurochemical effects observed in this model19,22. Special consideration should be given to the choice of the rat gender (males versus females)23, age (young versus old)24,25, diet26 and strain27, which can significantly influence the development of pain hypersensitivity following CCI.
Pain hypersensitivity testing, using an electronic von Frey aesthesiometer or manual von Frey hairs for mechanical withdrawal threshold and a plantar analgesia (Hargreaves) meter for thermal withdrawal latency, are well established and reliable quantitative measures of pain hypersensitivity in small animals. Their use, in combination with models of neuropathic pain, are widespread and allow for direct comparisons of paw sensitivity to mechanical and thermal stimuli across different treatment options, and between different strains of rats. It should be noted that other behavioural assays, such as the pin prick test and cold allodynia, are also used for testing CCI-induced pain hypersensitivity8.
While the use of reflexive withdrawal from mechanical or thermal stimuli is the major measure of neuropathic pain in this model and others, it has recently been criticised for its poor correlation with human symptoms and the involvement of considerable experimenter bias28. Therefore, the use of additional paradigms such as operant measures of pain29 and spontaneously emitted behaviours30 would be beneficial.
Nevertheless, despite these limitations, the CCI model and the paw withdrawal tests for measuring pain hypersensitivity are pivotal for understanding the mechanisms of neuropathic pain and identifying new analgesic targets. In our laboratory, we routinely perform CCI and measure mechanical paw withdrawal thresholds and thermal paw withdrawal latencies, in order to understand how neuro-immune interactions contribute to neuropathic pain31, and assess the potential of modulating the immune system to reduce pain hypersensitivity.